A Phase II Study of Zuberitamab Injection in Patients With Primary Membranous Nephropathy
Phase 2
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-10-15
- Last Posted Date
- 2024-10-15
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 135
- Registration Number
- NCT06642909
- Locations
- 🇨🇳
Zhongshan Hospital Fudan University, Shanghai, Shanghai, China
A Phase I Study of BR115 for Injection Alone in Subjects With Advanced Solid Malignancies
Phase 1
Not yet recruiting
- Conditions
- Interventions
- First Posted Date
- 2024-04-29
- Last Posted Date
- 2024-04-29
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT06388902
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
A Study of BRY805 in Participants With Advanced Solid Tumors
- First Posted Date
- 2024-03-04
- Last Posted Date
- 2024-03-04
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT06289894
- Locations
- 🇨🇳
Shandong Tumor hospital, Jinan, Shandong, China
Phase I Randomized, Open-label, Parallel-controlled, Pharmacokinetic and Safety Study of BR201 Injection Versus Cosentyx in Healthy Male Subjects
- First Posted Date
- 2023-11-13
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 88
- Registration Number
- NCT06126718
A Phase I Study of BRY812 for Injection Alone in Subjects With Advanced Malignancies
- First Posted Date
- 2023-09-14
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 164
- Registration Number
- NCT06038058
- Locations
- 🇨🇳
Sun Yat-sen Memorial Hospital，Sun Yat-sen University, Guangzhou, Guangdong, China
A Phase I Study of BR108 in Hematological Malignancies
- First Posted Date
- 2023-08-30
- Last Posted Date
- 2023-08-30
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT06018506
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China
A Phase I Study of BR101 Injection Alone in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-08-21
- Last Posted Date
- 2023-08-21
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 36
- Registration Number
- NCT06001580
- Locations
- 🇨🇳
The Second Affiliated Hospital of Zhejiang University Medical College, Hangzhou, Zhejiang, China
Phase I/II Clinical Study of 1A46 Drug Substance
- First Posted Date
- 2023-08-14
- Last Posted Date
- 2024-10-26
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 209
- Registration Number
- NCT05987605
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Phase I Clinical Study of BR105 Injection
- First Posted Date
- 2022-04-28
- Last Posted Date
- 2022-04-28
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 162
- Registration Number
- NCT05351697
- Locations
- 🇨🇳
Beijing Cancer Hospital, Beijing, Beijing, China
Comparison of Pharmacokinetics and Safety of HS627(2 Specifications) Versus PERJETA With a Single Injection
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2022-04-12
- Last Posted Date
- 2023-07-11
- Lead Sponsor
- BioRay Pharmaceutical Co., Ltd.
- Target Recruit Count
- 180
- Registration Number
- NCT05323981
- Locations
- 🇨🇳
The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China
© Copyright 2024. All Rights Reserved by MedPath